Colitis ulcerosa: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• NLRP3 0
• NRF2 0
• STAT3 0
• JAK 2
• TNF 2
• IL-23 5
• TLR4 0
• MAPK 0
• PI3K 0
• PPAR 0
• AKT 0
• STING 0
• mTOR 0
• AMPK 0
• IL-6 0
• HIF-1 0
• TP53 0
• COX-2 0
• IL-17 0
• SIRT1 0
• CTNNB1 0
• GLP-1 0
• HMGB1 0
• HSP90 0
• IL-1 0
• CD40 0
• HDAC 1
• MMP-9 0
• GPX4 0
• JNK 0
• YAP 0
• EGFR 0
• CD19 3
• CTLA-4 0
• IL-4 0
• METTL3 0
• PARP 0
• VEGF 0
• BCMA 3
• ERK 0
• FOXP3 0
• MUC1 0
• PINK1 0
• ACE2 0
• G6PD 0
• IL-15 1
• KEAP1 0
• LRRK2 0
• MDM2 0
• PD-1 0
• PD-L1 0
• PKM2 0
• TIGIT 0
• BRD4 0
• CCR5 0
• CD30 0
• EZH2 0
• IL-13 0
• MYC 0
• PDE4 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDDK · R01

  Stem- and Paneth cell-specific CD74 functions control gut immune responses

  Rutgers Biomedical and Health Sciences· Newark, Egyesült Államok· 780 495 USD awarded in fiscal year 2026· until 2030. jún.

• NIH NIDDK · SB1

  Development of TP-317 for Ulcerative Colitis

  Thetis Pharmaceuticals, Llc· Deep River, Egyesült Államok· 669 925 USD awarded in fiscal year 2026· until 2028. júl.

• NIH NIDDK · R01

  Identification of bacterial derived proteases that inhibit inflammation and pain signaling in the gut

  Stanford University· Stanford, Egyesült Államok· 3 802 100 USD awarded in fiscal year 2026· until 2030. aug.

• NIH NIDDK · R44

  An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel Disease

  Gentibio, Inc.· Cambridge, Egyesült Államok· 1 061 227 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIDDK · R01

  Per- and poly-fluoroalkyl substances (PFAS) exposure and glycosylation alterations preceding inflammatory bowel disease

  Icahn School of Medicine at Mount Sinai· New York, Egyesült Államok· 698 943 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Microbiota-Ulcerative Colitis INterface: Phage-bacteria-immune interactions at the mucosal level. (MUCIN)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 217 076 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Characterising the molecular and cellular basis of enteric nervous system alterations in the inflamed gut (NeurogENSity)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 206 888 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A Fibroblast-Targeting Advanced Lead Mitigating Inflammation and Fibrosis in IBD (FIBROLEAD)

  Inolysis Monoprosopi Idiotiki Kefalaiouchiki Etaireia· Melissia Athens, Görögország· EU contribution 150 000 EUR· until 2027. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Unravelling neuroimmune crosstalk to find novel treatment targets for inflammatory bowel disease (UNTANGLED)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 432 468 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interplay of epithelial mechanics and neutrophil activation as a pathomechanism in refractory IBD and colorectal cancer patients (INTERCONNECTIONS)

  Universitatsklinikum Erlangen· Erlangen, Németország· EU contribution 173 847 EUR· until 2026. dec.

10 of 225 running projects, newest first. Listed amounts together: 115,8 M USD + 19,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 25
• Organoids 15
• Mendelian Randomization Analysis 48
• Gene Expression Profiling 76
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 29
• Metabolomics 48
• Mass Spectrometry 5
• Flow Cytometry 8
• Immunohistochemistry 18
• Magnetic Resonance Imaging 10
• Machine Learning 43
• Deep Learning 11
• Cohort Studies 90
• Genome-Wide Association Study 56

• Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study.

  Inflamm Bowel Dis, 2026. okt.

• Hemp seed oil ameliorates DSS-induced ulcerative colitis in mice by altering transcriptomics and metabolomics.

  J Nat Med, 2026. szept.

• Integrated microbiome and metabolomics analysis of the mechanism of inflammation-reducing effects of cyanidin-3-glucoside and blueberry pectin complexes in mice with ulcerative colitis.

  Int J Biol Macromol, 2026. aug.

• Integrated multi-omics, network pharmacology, and experimental validation reveal the protective mechanisms of curcumol against DSS-induced ulcerative colitis.

  Front Immunol, 2026. aug.

• Integrated Multi-Omics Analysis of Antarctic Krill Oil in Alleviating DSS-Induced Colitis and Modulating Gut Microbiota in Mice.

  Mar Drugs, 2026. aug.

• Mechanism and active ingredients of Gancao Qinlian Granules in ameliorating ulcerative colitis:integrated in vivo, in vitro, network pharmacology and untargeted metabolomics investigation.

  J Ethnopharmacol, 2026. aug.

• Urinary Organic Acid Profiling by GC-MS Reveals Distinct Metabolic Signatures for Non-Invasive Diagnosis and Disease Activity Monitoring of Inflammatory Bowel Disease.

  Int J Mol Sci, 2026. júl.

• Pharmacokinetic characteristics of Bletilla Striata active components in rats and 1H NMR metabolomics study on ulcerative colitis.

  Fitoterapia, 2026. júl.

• Role of Fatty Acid Oxidation in Crohn's Disease and Ulcerative Colitis: Metabolomics Analysis and Experimental Evidence.

  Cell Biochem Funct, 2026. júl.

• Metabolomics profiling and anti-colitic activity of Rudbeckia hirta aerial parts: Inhibition of NF-κB, cytokine storm, and chemokine-mediated immune cell recruitment.

  J Ethnopharmacol, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.